| Literature DB >> 34151032 |
Gabriel Arantes Dos Santos1, Ruan Pimenta1, Nayara I Viana1,2, Vanessa R Guimarães1, Poliana Romão1, Patrícia Candido1, Juliana A de Camargo1, Diná M Hatanaka3, Paula Gs Queiroz3, Alexandre Teruya3, Katia R M Leite1, Victor Srougi1,3, Miguel Srougi1, Sabrina T Reis1,3,2.
Abstract
The infection by COVID-19 is a serious global public health problem. An efficient way to improve this disease's clinical management would be to characterize patients at higher risk of progressing to critically severe infection using prognostic biomarkers. The telomere length could be used for this purpose. Telomeres are responsible for controlling the number of maximum cell divisions. The telomere length is a biomarker of aging and several diseases. We aimed to compare leukocyte telomere length (LTL) between patients without COVID-19 and patients with different clinical severity of the infection. Were included 53 patients who underwent SARS-CoV-2 PCR divided in four groups. The first group was composed by patients with a negative diagnosis for COVID-19 (n = 12). The other three groups consisted of patients with a confirmed diagnosis of COVID-19 divided according to the severity of the disease: mild (n = 15), moderate (n = 17) and severe (n = 9). The LTL was determined by Q-PCR. The severe group had the shortest LTL, followed by the moderate group. The negative and mild groups showed no differences. There is an increase of patients with hypertension (p = 0.0099) and diabetes (p = 0.0067) in moderate and severe groups. Severe group was composed by older patients in comparison with the other three groups (p = 0.0083). Regarding sex, there was no significant difference between groups (p = 0.6279). In an ordinal regression model, only LTL and diabetes were significantly associated with disease severity. Shorter telomere length was significantly associated with the severity of COVID-19 infection, which can be useful as a biomarker or to better understand the SARS-CoV-2 pathophysiology.Entities:
Keywords: Biomarker; COVID-19; Prognostic; Telomere length
Year: 2021 PMID: 34151032 PMCID: PMC8200309 DOI: 10.1016/j.bbrep.2021.101056
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Fig. 1Comparison between LTL of groups I, II, III and IV. The telomere length was normalized by a single copy gene. The y axis is in arbitrary unit. The p value is determined by Kruskal-Wallis test.
Patients characteristics.
| Group | I | II | III | IV | p-value |
|---|---|---|---|---|---|
| Age (mean) | |||||
| 39.8 (±11.37) | 47.47 (±11.62) | 40.47 (±11.34) | 56.11 (±11.72) | ||
| 6 | 7 | 5 | 3 | 0.6279 | |
| 6 | 8 | 12 | 6 | ||
| 11 | 13 | 13 | 3 | ||
| 1 | 2 | 4 | 6 | ||
| 12 | 15 | 12 | 5 | ||
| 0 | 0 | 5 | 4 | ||
Ordinary one-way ANOVA.
Chi-square.
Ordinal regression model between risk factors and COVID-19 severity.
| Parameter Estimates | |||
|---|---|---|---|
| Group* | Parameter | Odds Ratio | p-value |
| III | Sex | 0.114 | 0.82 |
| Age | 12.87 | 0.54 | |
| LTL | 0.043 | ||
| Diabetes | 1.88 × 10-10 | ||
| Hypertension | 2.118 | 0.691 | |
| IV | Sex | 0.105 | 0.116 |
| Age | 3.327 | 0.458 | |
| LTL | 0.002 | ||
| Diabetes | 1.25 × 10-10 | ||
| Hypertension | 0.225 | 0.36 | |
This reduced model is equivalent to the final model because omitting the effect does not increase the degrees of freedom. * The reference category is group II.